Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating on GitLab Inc (GTLB) Amid Acquisition Speculation
-
Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM) on Dual-Program Growth Potential
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT) After Management Meet
-
Disc Medicine announces $220M public stock offering
-
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
ACG METALS LIMITED: Q3 2025 YTD Operations and Capital Structure Update
-
Freddie Mac Announces Results of Tender Offer for Certain STACR Notes
-
Cantor Fitzgerald Reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA): Notes Patent Potential
-
Cantor Fitzgerald Reiterates Overweight Rating on Artiva Biotherapeutics (ARTV) on NK Therapy Progress
-
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA): Says it's Undervalued
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY) Amid GLP-1 Pricing Uncertainty
-
Cantor Fitzgerald Reiterates Overweight Rating on Esperion Therapeutics (ESPR): Says Expenses Manageable
-
Cantor Fitzgerald Reiterates Overweight Rating on Oracle (ORCL): Notes Strong AI Pipeline, OCI Growth
-
Disc Medicine (IRON) PT Raised to $153 at Cantor Fitzgerald After FDA Priority Voucher Win
-
Planet Labs (PL) PT Raised to $20 at Cantor Fitzgerald on Sales Growth, Margin Outlook
-
Lexeo Therapeutics prices $135 million public offering at $8 per share
-
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
-
Form 424B3 Cantor Fitzgerald Income
-
Lexeo Therapeutics launches stock offering and private placement
-
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
-
Satellogic prices $90 million stock offering at $3.25 per share
-
Satellogic Announces Pricing of $90 Million Public Offering of Class A Common Stock
-
Lancium Secures $600 Million Debt Financing to Advance Clean Campus Development, Starting with 1.2 GW Abilene Site
-
M3-Brigade Acquisition VI Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing October 17, 2025
-
FB Financial (FBK) PT Raised to $66 at Cantor Fitzgerald on Growth Outlook
-
Cantor Fitzgerald Reiterates Salesforce's (CRM) Overweight Rating on AI Strategy, Slack Integration
-
Cantor Fitzgerald Reiterates Meta Platform's (META) Overweight Rating on AI Momentum, Sentiment Reversal
-
Cantor Fitzgerald Assumes Verastem (VSTM) at Overweight
-
Fossil extends exchange offer deadline for senior notes
-
Fossil Announces Further Extension of Exchange Offer for Its Senior Notes
-
Form SCHEDULE 13D/A XBP Global Holdings, Filed by: CANTOR FITZGERALD, L. P.
-
Orchid Island Capital Announces Estimated Third Quarter 2025 Results, October 2025 Monthly Dividend and September 30, 2025 RMBS Portfolio Characteristics
-
Satellogic announces public offering of Class A common stock
-
Satellogic Announces Proposed Public Offering of Class A Common Stock
-
Cantor Fitzgerald Starts Nuvalent (NUVL) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on HubSpot Inc (HUBS) on Data Hub, AI Potential
-
Cantor Fitzgerald Reiterates Overweight Rating on Aclaris Therapeutis (ACRS): 2026 Rich in Catalysts
-
Cantor Fitzgerald Reiterates Overweight Rating on Xencor, Inc. (XNCR) Ahead of 10/24 Webcast
-
BioCryst Pharma (BCRX) PT Raised to $26 at Cantor Fitzgerald After Astria (ATXS) Acquisition
-
Cantor Highlights Cybin's (CYBN) CYB003’s Potential to Shift MDD Treatment
-
Cantor Fitzgerald Reiterates Overweight Rating on Cybin Inc. (CYBN)
-
ASP Isotopes Inc. Announces Pricing of Public Offering of Common Stock
-
Cantor Fitzgerald Says Phathom Pharmaceuticals (PHAT) is Top Pick After Focusing on GI
-
Cantor Fitzgerald Reiterates Overweight Rating on Eve Holding Inc. (EVEX), Says Undervalued
-
ASP Isotopes announces underwritten public offering of common stock
-
ASP Isotopes Inc. Announces Proposed Public Offering of Common Stock
-
IREN Ltd. (IREN) PT Raised to $100 at Cantor Fitzgerald on AI Cloud Growth Potential
-
Predictive Oncology adds executives to support digital asset strategy
-
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
-
GOWell Technology Limited, an Innovative Leader in Well Logging Technologies for the Energy Sector, to Go Public Via Business Combination With Inflection Point-Led SPAC

